AMEX · LCTX
Healthcare · Biotechnology
$0.97
Down-$0.03 (-3.25%)
Updated Oct 21, 2026, 6:55 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LCTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 20, 2026
LCTX closed at $0.97 after 21 trading sessions, down 6.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | $0.9508 | $1.01 | $0.9508 | $0.9726 | 1.63M |
| Oct 19, 2026 | $0.9809 | $0.9997 | $0.94 | $0.9528 | 955.55K |
| Oct 16, 2026 | $0.98 | $1.00 | $0.96 | $0.9783 | 1.31M |
| Oct 15, 2026 | $0.9212 | $0.9994 | $0.918 | $0.9903 | 1.42M |
| Oct 14, 2026 | $0.9142 | $0.94 | $0.8902 | $0.9175 | 2.2M |
| Oct 13, 2026 | $0.95 | $0.97 | $0.895 | $0.9083 | 1.78M |
| Oct 12, 2026 | $0.9979 | $0.9979 | $0.9383 | $0.9541 | 1.69M |
| Oct 9, 2026 | $1.02 | $1.025 | $0.98 | $0.994 | 1.16M |
| Oct 8, 2026 | $0.9494 | $1.045 | $0.93 | $1.03 | 2.01M |
| Oct 7, 2026 | $0.9424 | $0.965 | $0.9212 | $0.9476 | 1.48M |
| Oct 6, 2026 | $0.9411 | $0.965 | $0.925 | $0.9379 | 967.62K |
| Oct 5, 2026 | $0.93 | $0.9604 | $0.9118 | $0.9274 | 1.39M |
| Oct 2, 2026 | $0.921 | $0.96 | $0.8913 | $0.9303 | 1.25M |
| Oct 1, 2026 | $0.9581 | $0.97 | $0.8823 | $0.9042 | 1.65M |
| Sep 30, 2026 | $0.9503 | $0.9882 | $0.9421 | $0.9557 | 1.27M |
| Sep 29, 2026 | $0.98 | $0.99 | $0.9203 | $0.9475 | 2.59M |
| Sep 28, 2026 | $1.02 | $1.04 | $0.96 | $0.971 | 1.57M |
| Sep 25, 2026 | $0.95 | $1.04 | $0.9419 | $1.03 | 2.48M |
| Sep 24, 2026 | $0.9519 | $0.9692 | $0.9101 | $0.9478 | 2.44M |
| Sep 23, 2026 | $1.02 | $1.04 | $0.9551 | $0.9567 | 2.63M |
| Sep 22, 2026 | $1.02 | $1.05 | $1.00 | $1.04 | 847.53K |
The latest Smart Investors Daily articles mentioning LCTX.
Company
Market Activity
Research & News
LCTX research
Company profile and research snapshot.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | HC Wainwright & Co. | Buy | — |
| May 4, 2026 | D. Boral Capital | Buy | — |
| Apr 28, 2026 | Canaccord Genuity | Buy | — |
| Mar 25, 2026 | B. Riley Securities | Buy | — |
| Mar 24, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 12, 2026
On Thursday, Lineage Cell Therapeutics (AMEX:LCTX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For
Yahoo · Sep 16, 2026
Rising rates are squeezing indebted businesses. Meet three small cap stocks with strong revenue growth and low debt, plus a screener to find more like them.
Yahoo · Sep 8, 2026
CARLSBAD, Calif., September 08, 2026--AlloSCOPE 5D Patent Release
SeekingAlpha · Sep 1, 2026
Lineage Cell Therapeutics is rated Hold due to its reliance on out-licensing and a risk-adjusted fair value below the current share price. Click for more.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LCTX.
